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Background:  Clostridium  difﬁcile,  a major  cause  of  nosocomial  and  antibiotic-associated  diarrhea,  carries
a  signiﬁcant  disease  and  cost  burden.  This  study  aimed  to select  an  optimal  formulation  and  schedule  for
a candidate  toxoid  vaccine  against  C.  difﬁcile  toxins  A and B.
Methods:  Randomized,  placebo-controlled,  two-stage,  Phase  2  study  in  a  total  of  661 adults  aged 40–75
years.  Stage  I:  low  (50  g antigen)  or  high  (100  g antigen)  dose  with  or without  aluminum  hydrox-
ide (AlOH)  adjuvant,  or  placebo,  administered  on  Days  0–7–30. Stage  II: Days  0–7–30, 0–7–180,  and
0–30–180, using  the  formulation  selected  in Stage  I through  a decision  tree  deﬁned  a  priori  and  based
principally  on  a  bootstrap  ranking  approach.  Administration  was  intramuscular.  Blood  samples  were
obtained  on Days  0,  7, 14,  30,  60 (Stage  I and  II), 180,  and  210  (Stage  II);  IgG to toxins  A and  B was  mea-
sured  by ELISA  and  in vitro  functional  activity  was  measured  by  toxin  neutralizing  assay  (TNA).  Safetylostridium difﬁcile
data  were  collected  using  diary  cards.
Results:  In Stage  I the  composite  immune  response  against  toxins  A and  B (percentage  of  participants
who  seroconverted  for  both  toxins)  was  highest  in  the  high  dose  + adjuvant  group  (97% and  92% for
Toxins  A and B,  respectively)  and  was  chosen  for  Stage  II.  In  Stage  II the  immune  response  proﬁle  for
this  formulation  through  Day  180  given  on Days 0–7–30 ranked  above  the other  two  administration
schedules.  There  were  no safety  issues.
 Data presented at the 24th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 10–13 May  2014, Barcelona, Spain, and
he  114th General Meeting of the American Society for Microbiology (ASM), 17–21 May 2014, Boston, USA.
∗ Corresponding author at: Sanoﬁ Pasteur, Discovery Drive, Swiftwater, PA 18370-0187, USA. Tel.: +1 570 957 0746.
E-mail address: guy.debruyn@sanoﬁpasteur.com (G. de Bruyn).
1 Present address: Sunovion Pharmaceticals, Inc., Marlborough, MA,  USA.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.028
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
.0/).
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Conclusions:  The  high  dose  + adjuvant  (100  g antigen  + AlOH)  formulation  administered  at  0–7–30 days
elicited the  best  immune  response  proﬁle,  including  functional  antibody  responses,  through  Day  180  and
was  selected  for  use  in  subsequent  clinical  trials.
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. Introduction
Clostridium difﬁcile (C. difﬁcile) is a gram-positive, spore-forming
naerobe, which causes colonic mucosal injury and inﬂamma-
ion by the release of toxins A (a 308 kDa enterotoxin) and B
a 270 kDa cytotoxin) [1]. While carriage of the organism may
e asymptomatic, C. difﬁcile is a major cause of nosocomial and
ntibiotic-associated diarrhea in Europe and North America, and
evere cases can lead to pseudomembranous colitis and toxic mega-
olon [2,3]. C. difﬁcile infection (CDI) imposes a signiﬁcant burden
f disease [4] and infection rates have increased substantially over
ecent years. In the US alone, recent data suggest almost 500,000
nfections and approximately 29,000 deaths in 2011 [5]. As well as
ts importance as a nosocomial infection, C. difﬁcile is also increas-
ngly present in the community [6] and the ﬁnancial burden is high,
eing estimated at over $7 billion annually in Europe [7] and the
S [8,9] combined.
Given the limitations of current treatment options, the high
ates of recurrence [8,10–12], and with C. difﬁcile spores tolerating
ost disinfection procedures [13], combatting CDI by targeted dis-
ase prevention is ideal. Toxins A and B both damage colonic cells,
nd studies have suggested a relationship between the immune
esponse to these toxins and protection against CDI [14–18]. No
accine is available against CDI, however a bivalent, toxoid vaccine
o stimulate immunity to toxins A and B and negate their harmful
ffects is currently being developed [19]. Phase 1 data have shown
ood tolerability and a strong immune response to both toxins in
dults including the elderly [20]. Crucial to the continued clinical
evelopment of this candidate vaccine is a robust assessment of a
ange of formulations and dosing schedules. This study was  con-
ucted to identify the formulation and schedule to be used in later
hase clinical studies. As such, Stage I of the study was designed to
ssess the safety and immunogenicity of four formulations (high or
ow dose of antigen, with or without adjuvant) administered in the
ame schedule and Stage II assessed two further schedules using
he formulation selected in Stage I.
. Methods
.1. Study design and participants
This randomized, placebo controlled, Phase 2 study was  con-
ucted in two stages in 39 centers in the USA. In Stage I a range
f doses (low [50 g total antigen] or high [100 g total antigen])
nd formulations (with or without aluminum hydroxide adjuvant)
ere assessed for a candidate C. difﬁcile vaccine using the same
dministration schedule. In Stage II two additional schedules of
dministration were assessed using the formulation selected after
tage I. In Stage I the investigators, participants, outcome assessors,
nd laboratory personnel were blinded to the formulation admin-
stered. Stage II was open-label (except for laboratory personnel).
ocal independent ethics committees approved the study proto-
ol and amendments. The study was conducted according to the
pplicable local and national requirements, Good Clinical Practice
nd applicable International Conference on Harmonization guide-
ines, and conformed to the principles of the Declaration of Helsinki
Edinburgh revision, October 2000).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Each participant signed an informed consent form prior to
enrolment. Vaccine administration took place between 27 October
2010–15 June 2011 (Stage I) and 15 November 2011–23 July 2012
(Stage II) (ClinicalTrials.gov NCT01230957).
To be eligible, participants were aged between 40 and 75 years
(stratiﬁed into equal groups aged 40–64 years and 65–75 years
in each stage) and considered to be at risk of C. difﬁcile infection
based on (i) impending hospitalization within 60 days of enrolment,
or (ii) current or impending (within 60 days of enrolment) resi-
dence in a long-term care facility or rehabilitation facility. The main
exclusion criteria were: pregnancy or lack of effective contracep-
tion, participation in another clinical study, non-study vaccination
(other than inﬂuenza or pneumococcal vaccines) in the previous
4 weeks, previous vaccination against C. difﬁcile,  current or prior
episode of CDI, receipt of blood products in the previous 3 months,
congenital or acquired immunodeﬁciency or receipt of anti-cancer
chemo- or radiotherapy in the previous 6 months, >2 weeks cor-
ticosteroid therapy in the previous 3 months, seropositivity for
HIV/hepatitis B/hepatitis C, anticipated or current kidney dialy-
sis, hypersensitivity to any vaccine component, bleeding disorder
contraindicating intramuscular (IM) injection, chronic disease or
addiction that could interfere with study procedures, history of
diverticular intestinal bleeding, surgery for gastrointestinal malig-
nancy in the previous 3 months.
In Stage I, participants were randomized to one of ﬁve groups
and received three doses of vaccine (low or high dose with or with-
out adjuvant) or placebo at Days 0–7–30 (see Table 1). One of these
formulations was then selected for Stage II, based on immunogenic-
ity. In Stage II, additional participants were randomized to receive
the selected vaccine formulation according to two alternative vac-
cination schedules: Days 0–7–180, or 0–30–180. All injections were
intramuscular (IM), ideally into alternate arms for sequential vac-
cinations.
2.2. Vaccines
The investigational C. difﬁcile toxoid vaccine was  a formalin-
inactivated, highly puriﬁed preparation of toxoids A and B, and
presented as a freeze-dried preparation that was reconstituted with
diluent (either adjuvant or water for injection) prior to IM injection
(0.5 mL). The adjuvant was 400 g AlOH provided as 1600 g/mL
in water for injection. Placebo was 0.9% saline.
2.3. Serology
Blood samples were collected on Days 0, 7, 14, 30, 60 (all partic-
ipants), 180, and 210 (all participants in Stage II and those in Stage I
who received the formulation selected for Stage II), and analyzed for
(i) serum anti-toxin IgG to C. difﬁcile toxins A and B (enzyme-linked
immunosorbent assay [ELISA]), and (ii) anti-toxin A and B neutral-
izing capacity (toxin neutralizing assay [TNA]). All analyses were
conducted centrally at the Sponsor’s Global Clinical Immunology
laboratory.For the ELISA, full-length C. difﬁcile toxin A or toxin B was used to
coat ELISA plates. All controls, reference, and samples were added
to the microtiter plates, incubated at 37 ◦C followed by incubating
with goat anti-human IgG conjugated to horseradish peroxidase.
2172 G. de Bruyn et al. / Vaccine 34 (2016) 2170–2178
Table 1
Summary of seroconversion rates measured by ELISA (Day 0–210) (PP set).
Stage I Stage II
Toxin
Day
Group 1
(N = 69)
Group 2
(N = 68)
Group 3
(N = 64)
Group 4
(N = 71)
Group 5
(N = 38)
Group 6
(N = 61)
Group 7
(N = 57)
Toxin A
Day 7 NA NA 10.6 (4.4;20.6) NA NA 5.0 (1.0;13.9) 8.8 (2.9;19.3)
Day  14 36.2 (25.0;48.7) 30.9 (20.2;43.3) 27.7 (17.3;40.2) 26.8 (16.9;38.6) 0.0 (0.0;9.3) 37.7 (25.6;51.0) 29.8 (18.4;43.4)
Day  30 74.3 (62.4; 84.0) 48.5 (36.2;61.0) 67.7 (55.0;78.8) 60.6 (48.3;72.0) 5.3 (0.6;17.8) 67.2 (54.0;78.7) 50.9 (37.3;64.4)
Day  60 94.2 (85.8;98.4) 95.6 (87.6;99.1) 97.0 (89.5;99.6) 90.1 (80.7;95.9) 7.9 (1.7;21.4) 65.6 (52.3;77.3) 91.2 (80.7;97.1)
Day  180 NA NA 84.8 (73.9;92.5) NA NA 50.8 (37.7;63.9) 71.9 (58.5;83.0)
Day  210 NA NA 81.8 (70.4;90.2) NA NA 100.0 (94.1;100.0) 100.0 (93.7;100.0)
Toxin  B
Day 7 NA NA 12.1 (5.4;22.5) NA NA 24.6 (14.5;37.3) 17.5 (8.8;29.9)
Day  14 57.1 (44.8;68.9) 45.6 (33.5;58.1) 57.6 (44.8;69.7) 58.9 (46.8;70.3) 2.6 (0.1;13.8) 68.9 (55.7;80.1) 59.6 (45.8;72.4)
Day  30 75.7 (64.0;85.2) 60.3 (47.7;72.0) 71.2 (58.8;81.7) 67.1 (55.1;77.7) 7.9 (1.7;21.4) 85.2 (73.8;93.0) 73.7 (60.3;84.5)
Day  60 85.7 (75.3;92.9) 82.4 (71.2;90.5) 92.4 (83.2;97.5) 93.2 (84.7;97.7) 13.2 (4.4;28.1) 85.2 (73.8;93.0) 89.5 (78.5;96.0)
Day  180 NA NA 74.2 (62.0;84.2) NA NA 62.3 (49.0;74.4) 71.9 (58.5;83.0)
Day  210 NA NA 69.7 (57.2;80.4) NA NA 93.4 (84.1;98.2) 93.0 (83.0;98.1)
Compositea
Day 7 NA NA 4.5 (1.0;12.7) NA NA 5.0 (1.0;13.9) 3.5 (0.4;12.1)
Day  14 29.0 (18.7;41.2) 29.4 (19.0;41.7) 24.6 (14.8;36.9) 25.4 (15.8;37.1) 0.0 (0.0;9.3) 36.1 (24.2;49.4) 22.8 (12.7;35.8)
Day  30 62.9 (50.5;74.1) 38.2 (26.7;50.8) 46.2 (33.7;59.0) 50.7 (38.6;62.8) 2.6 (0.1;13.8) 62.3 (49.0;74.4) 42.1 (29.1;55.9)
Day  60 85.5 (75.0;92.8) 82.4 (71.2;90.5) 90.9 (81.3;96.6) 87.3 (77.3;94.0) 7.9 (1.7;21.4) 60.7 (47.3;72.9) 84.2 (72.1;92.5)
Day  180 NA NA 68.2 (55.6;79.1) NA NA 37.7 (25.6;51.0) 54.4 (40.7;67.6)
Day  210 NA NA 62.1 (49.3;73.8) NA NA 93.4 (84.1;98.2) 93.0 (83.0;98.1)
Data are percentage of participants with a ≥4-fold increase from Day 0 (95% CI).
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a Composite indicates when a participant demonstrated a ≥4-fold increase for bo
fter exposure to peroxidase enzyme substrate, plates were read
y an ELISA plate reader using SoftMax Pro software. The average
ptical density (OD) value for the plate blank was subtracted from
ll the ODs within each plate. The concentration of antibodies in
erum was then derived by extrapolating from a standard curve.
he reference standard consisted of pooled human plasma from
reviously immunized subjects. The reference was  assigned a value
f 100 EU/mL, thus quantitative results were reported in EU/mL.
For the TNA, serial dilutions of sera were mixed with C. difﬁcile
hallenge toxin and incubated with cultured Vero cells that are sen-
itive to the toxin. The OD of each plate was read at 562 nm (signal)
nd 630 nm (background). The 50% speciﬁc signal was determined
y SoftMax Pro software for each plate. The titer of neutralizing
ntibodies for the sample tested is the reciprocal ﬁnal dilution cor-
esponding to the 50% speciﬁc signal. The 50% signal was  the OD
alue of the cell control plus one half the difference between the
oxin control and cell control. The titer was determined by inter-
olation of the dilution corresponding to the 50% speciﬁc signal.
.4. Reactogenicity and safety
Pre-deﬁned (solicited) adverse events (AEs) were automatically
onsidered to be related to vaccination (adverse reactions [ARs]):
olicited injection site (pain, erythema, swelling) and systemic
fever, headache, malaise, myalgia, arthralgia) ARs were collected
n the day of vaccination and for 6 days after each vaccination.
nsolicited AEs were collected for 30 days after each vaccination.
erious adverse events (SAEs) were collected throughout the study.
he relationship of unsolicited AEs and SAEs to vaccination was
ssessed by the investigator.
.5. Biological safetyIn Stage II only, blood and urine samples were taken on Days
, 14, and 210 for hematology (hemoglobin, white blood cells
WBCs], lymphocytes, neutrophils, eosinophils, platelets), serum
iochemistry (sodium, potassium, glucose, creatinine, albumin,ants available for a particular timepoint).
ins.
liver function tests), and urinalysis (protein, glucose, red blood cells,
WBCs). All analyses were done at local laboratories.
2.6. Statistical analyses
All analyses were descriptive, with no hypotheses tested. The
primary objectives were to describe the safety proﬁle and the
immune response elicited by the C. difﬁcile toxoid vaccine candi-
date, with the aim of selecting a vaccine formulation and dosing
schedule for further clinical development. A per protocol (PP)
analysis set was  deﬁned for immunogenicity based on meeting
inclusion/exclusion criteria, receipt of the correct number of doses,
receipt of the correct formulation administered according to the
protocol and in the proper time window, provision of pre- or
post-dose 1 serology samples according to protocol-deﬁned time
windows, protocol deviations, lack of a valid serology result pre-
or post-dose 1. A safety analysis set, including all participants who
received at least one trial vaccination, was used for the safety anal-
yses. For the main parameters, 95% conﬁdence intervals (CIs) of
point estimates were calculated using the normal approximation
for quantitative data and the exact binomial distribution for pro-
portions [21].
For the selection of the formulation for Stage II, a bootstrap
analysis was  done using the data to Day 60 from Stage I. A sim-
ilar analysis was done for the selection of the optimal schedule
using the data through Day 210 in Stage II. A pre-speciﬁed rank-
ing/selection analysis based on the immunogenicity outcomes was
applied to choose the best formulation in Stage I and the best
schedule in Stage II. Geometric mean concentrations (GMCs) of IgG
against each toxin (measured by ELISA) were ranked both sepa-
rately and as a composite (A and B). For Stage I, the probability of a
treatment group being ranked number 1 was determined based on
the Day 60 GMCs. In the absence of one treatment group reach-
ing 80% probability, ranking was applied to Day  30 and Day 14
data. Similarly for Stage II, the probability of a schedule being
ranked number 1 was  determined based on the Day 60 GMCs. In
the absence of one schedule reaching 80% probability, ranking was
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pplied to Day 14 and Day 210 data. The formulation selection was
ased primarily on the ELISA IgG results, with TNA results being
upportive, and the immune response in the older age stratum
65–75 years of age) participants was also considered in the choice
f formulation.
Being a descriptive study, the sample size calculation was
ot hypothesis-driven. With 100 participants planned per vaccine
roup and 50 in the placebo group there was a 95% probability of
etecting an AE with a true incidence of 3.0% and 5.8%, respectively.
. Results
.1. Participants studied
A total of 455 participants were enrolled into Stage I (101 par-
icipants in Groups 1, 2, and 3; 102 participants in Group 4; 50
articipants in Group 5), and 206 enrolled into Stage II (103 in
ach of Group 6 and Group 7) (Fig. 1). Of these, 416 (91.4%) par-
icipants completed Stage I to Day 60 (89 [88.1%], 95 [94.1%], 94
93.1%], 90 [88.2%] and 48 [96.0%] participants in Groups 1, 2, 3, 4
nd 5, respectively) and 168 (81.6%) participants completed Stage
I (89 [86.4%] and 79 [76.7%] in Groups 6 and 7, respectively). Age,
thnicity, and gender were comparable in each group. There were
o important differences between the two age ranges in terms of
afety and immunogenicity and so only the pooled data for the age
ange 40–75 years are presented.The majority of participants (597 [90.5%]) had a planned hos-
ital stay at enrolment and of these the majority (509 [85.3%])
ere admitted to hospital prior to receiving the third dose of study
accine.
STAGE I 455 participants randomize d to rece ive
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N=93
Dose 3
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Group 1 Group 2 Group
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N=101
Dose 2
N=98
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N=10
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Dose
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Completed
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Completed
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to AE (N=4 )
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3.2. Serology
3.2.1. Stage I
The GMC  responses (ELISA) for Groups 1–5 on Days 0, 14, 30,
and 60 are presented in Fig. 2 (data presented in Supplementary
Table 1) and seroconversion rates (percentage of participants with
a ≥4-fold increase from Day 0) are presented in Table 1. Following
vaccination on Days 0, 7 and 30, there was a steady increase in GMC
in Groups 1–4 (active vaccine groups) peaking at Day 60 for toxins
A and B. At Day 60, for toxin A, Group 3 (100 g + AlOH) showed
the highest GMC  response (91.5 EU/mL) and also the highest sero-
conversion rate (97%); for toxin B, GMC  was highest in Group 4
(high dose, no adjuvant) (156.8 EU/mL) while seroconversion rate
remained highest in Group 3 (92%). The composite seroconver-
sion rate for toxins A and B (i.e. the percentage of participants
who seroconverted for both toxins) was highest in Group 3 (91% at
Day 60).
For TNA, GMTs are presented in Fig. 2 and in Supplementary
Table 2, and seroconversion rates are presented in Table 2. These
data at Day 60 tended to favor Group 3 for toxin A and Group 4
for toxin B (however, for the elderly participants these data were
preferable in Group 3 [for participants 65–75 years of age, the Day
60 Toxin A GMT  in Group 3 was 568.8 1/dil (95% CI: 352.5; 918.0)
and Group 4 was  372.1 1/dil (95% CI: 178.5; 775.9) and the Day 60
Toxin B GMT  in Group 3 was 289.0 1/dil (95% CI: 116.1; 719.4) and
in Group 4 was  288.1 1/dil (95% CI: 91.2; 910.2]). Seroconversion
rate data at Day 60 were highest in Group 3 for toxin A (97.0%) and
similar for toxin B in Groups 3 and 4 (63.6% and 67.1%, respectively)
(the composite seroconversion rate was also similar on Groups 3
and 4, being 62.1% and 64.4%, respectively).
d 3-dose schedu le on Days 0, 7, 30
 adjuv ant
n + AlOH)
1
High  dose, no adjuvant
(100 µg anti gen)
N=102
Place bo
(0.9% saline)
N=50
 3 Group 4 Group 5
 1
1
 2
7
 3
3
Dose 1
N=102
Dose 2
N=95
Dose 3
N=90
Dose 1
N=50
Dose 2
N=48
Dose 3
N=48
ted
4
mplete:
liance 
 
l no t due 
5)
Completed
N=90
12 did not complete:
• Seriou s AE (N=2 )
•  Non-seriou s AE 
(N=2 )
• Non-compliance 
(N=1 )
• Voluntary 
withdrawal no t due 
to AE (N=7 )
Completed
N=48
2 did no t complete:
•  Voluntary 
withdrawal no t due 
to AE (N=2)
ELE CTE D FOR 
 II
 disposition.
2174 G. de Bruyn et al. / Vaccine 34 (2016) 2170–2178
STAGE II: 
STAGE II:
205 participants received 3-dose schedule of high dose + adjuvant 
(100 µg +AlOH) on either Days 0, 7, 180 or Days 0, 30, 180
High dose + adjuv ant
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Fig. 1. 
Based on these results, the 100 g + AlOH formulation (Group
) was selected as having the best overall immunogenic proﬁle and
n this basis was chosen for further evaluation in Stage II.
.2.2. Stage II
For Group 3 (0, 7, 30 day schedule) the GMCs for both toxins A
nd B peaked at Day 60, and were higher than for Group 6 (0, 7,
80 vaccination schedule) and Group 7 (0, 30, 180 day schedule)
t this time point (the latter two groups having received only the
rst two doses). In Group 3, GMCs for both toxins at Day 180 con-
inued to rank above Groups 6 and 7, but had decreased by Day 210
hereas in Groups 6 and 7 (both of which had a third vaccination
t Day 180) GMCs for both toxins increased markedly from Day
80 to Day 210, being similar in both groups. These data are pre-
ented graphically to Day 180 in Fig. 3 (the time period used for the
anking and choice of schedule); the data to Day 210 are presented
n Supplementary Table 3. Seroconversion rates for each toxin and
he composite seroconversion rate data (Table 1) showed the same
rends as the ELISA GMC  data, with the highest percentage of sero-
onverted participants being at Day 60 for Group 3 and Day 210 for
roups 6 and 7.
The TNA GMT  data (presented graphically to Day 180 in Fig. 3;
ata presented to Day 210 in Supplementary Table 4) supported thenot du e to AE (N=13)not du e to AE (N=7)
nued ).
trends described for the ELISA data, peaking at Day 60 for Group 3,
at which point GMTs were higher than for Groups 6 and 7. As for the
ELISA data, Group 3 GMT  data remained highest at Day 180 (except
for Toxin B, which was slightly higher for Group 7 [228.2 versus
175.4 1/dil]), and Groups 6 and 7 were highest by Day 210 (follow-
ing the third vaccination in these two latter groups at Day 180).
The TNA seroconversion data for both toxins and for the composite
response also conﬁrmed the evaluation based on the ELISA data,
with Group 3 being highest at Day 60 and Groups 6 and 7 being
highest at Day 210 (Table 2).
The bootstrap ranking analysis for the ELISA data at Day 60 in
Groups 3, 6, and 7 identiﬁed Group 3 as having at least 80% prob-
ability of being ranked ﬁrst for toxin B and for the composite data
(toxin A and B); toxin A for Group 3 was also ranked higher than
Groups 6 or 7.
Overall, the vaccination schedule in Group 3 (0, 7, 30 days) pro-
vided the highest immune response up to Day 180.
3.3. Safety and reactogenicity (Stage I and II)In all groups there were very few immediate AEs (occurring
in the 30 min  after vaccination). The incidence of solicited injec-
tion site and systemic reactions occurring in the 6 days after
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NFig. 2. Stage I: ELISA GMCs and TNA GMTs with as
accination was similar in each vaccine group, and higher than
or placebo (Table 3). In all groups, pain was the most common
njection site reaction and myalgia was the most common systemic
eaction; most were Grade 1 in intensity, began within the ﬁrst 3
ays, and had resolved within 3 days.
able 2
ummary of seroconversion rates measured by TNA (Day 0–210) (PP set).
Stage I 
Toxin
Day
Group 1
(N = 69)
Group 2
(N = 68)
Group 3
(N = 66)
Grou
(N =
Toxin A
Day 7 NA NA 13.6 (6.4;24.3) NA 
Day  14 40.0 (28.5;52.4) 30.9 (20.2;43.3) 31.8 (20.9;44.4) 42.5
Day  30 47.1 (35.1;59.5) 36.8 (25.4;49.3) 40.9 (29.0;53.7) 43.8
Day  60 91.4 (82.3;96.8) 75.0 (63.0;84.7) 97.0 (89.5;99.6) 82.2
Day  180 NA NA 92.3 (83.0;97.5) NA 
Day  210 NA NA 87.9 (77.5;94.6) NA 
Toxin  B
Day 7 NA NA 18.2 (9.8;29.6) NA 
Day  14 55.7 (43.3;67.6) 35.3 (24.1;47.8) 50.0 (37.4; 62.6) 52.1
Day  30 57.1 (44.8;68.9) 41.8 (29.9;54.5) 56.1 (43.3;68.3) 56.2
Day  60 60.0 (47.6;71.5) 50.0 (37.6;62.4) 63.6 (50.9;75.1) 67.1
Day  180 NA NA 53.0 (40.3;65.4) NA 
Day  210 NA NA 51.5 (38.9;64.0) NA 
Compositea
Day 7 NA NA 7.6 (2.5;16.8) NA 
Day  14 31.4 (20.9;43.6) 25.0 (15.3;37.0) 22.7 (13.3;34.7) 35.6
Day  30 38.6 (27.2;51.0) 28.4 (18.0;40.7) 30.3 (19.6;42.9) 32.9
Day  60 60.0 (47.6;71.5) 47.1 (34.8;59.6) 62.1 (49.3;73.8) 64.4
Day  180 NA NA 50.8 (38.1;63.4) NA 
Day  210 NA NA 47.0 (34.6;59.7) NA 
ata are percentage of participants with a ≥4-fold increase from Day 0 (95% CI).
 = number of participants included in the PP set (not necessarily the number of participa
A  = not applicable (group not selected for Stage II).
a Composite indicates when a participant demonstrated a ≥4-fold increase for both toxed 95% conﬁdence intervals (Groups 1–5) (PP set).
The incidence of unsolicited AEs after vaccination was compa-
rable between vaccine groups, ranging from 58.8% to 76.0%, and
similar to the placebo group (56.0%); those related to the vaccine
ranged from 9.8% to 20.6% for the vaccine groups with none in the
placebo group.
Stage II
p 4
 71)
Group 5
(N = 38)
Group 6
(N = 61)
Group 7
(N = 57)
NA 8.2 (2.7;18.1) 10.5 (4.0;21.5)
 (31.0;54.6) 0.0 (0.0;9.3) 39.3 (27.1;52.7) 42.1 (29.1;55.9)
 (32.2;56.0) 0.0 (0.0;9.3) 49.2 (36.1;62.3) 33.3 (21.4;47.1)
 (71.5;90.2) 0.0 (0.0;9.3) 41.0 (28.6;54.3) 82.5 (70.1;91.3)
NA 44.3 (31.6;57.6) 73.7 (60.3;84.5)
NA 100.0 (94.1;100.0) 100.0 (93.7;100.0)
NA 29.5 (18.5;42.6) 21.1 (11.4;33.9)
 (40.0;63.9) 0.0 (0.0;9.3) 54.1 (40.9;66.9) 56.1 (42.4;69.3)
 (44.1;67.8) 0.0 (0.0;9.3) 57.4 (44.1;70.0) 56.1 (42.4;69.3)
 (55.1;77.7) 5.3 (0.6;17.8) 57.4 (44.1;70.0) 63.2 (49.3;75.6)
NA 54.1 (40.9;66.9) 59.6 (45.8;72.4)
NA 86.9 (75.8;94.2) 89.5 (78.5;96.0)
NA 6.6 (1.8;16.0) 7.0 (2.0;17.0)
 (24.8;47.7) 0.0 (0.0;9.3) 32.8 (21.3;46.0) 33.3 (21.4;47.1)
 (22.3;44.9) 0.0 (0.0;9.3) 36.1 (24.2;49.4) 29.8 (18.4;43.4)
 (52.3;75.3) 0.0 (0.0;9.3) 31.1 (19.9;44.3) 56.1 (42.4;69.3)
NA 34.4 (22.7;47.7) 47.4 (34.0;61.0)
NA 86.9 (75.8;94.2) 89.5 (78.5;96.0)
nts available for a particular timepoint).
ins.
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NFig. 3. Stage II: ELISA GMCs and TNA GMTs with associate
No vaccine-related SAEs were reported; there were four deaths
one in Group 3, two in Group 6, and one in Group 7) but none was
onsidered to be related to the vaccine.
.4. Biological safety (Stage II only)
Although there were occasional out of range values that were
f clinical signiﬁcance, these were generally associated with
nderlying medical conditions and not unexpected for this study
opulation. None was considered to be related to the vaccine, and
one was of clinical importance in the context of this study.
. DiscussionThis Phase 2 study was conducted to deﬁne the optimal formu-
ation and vaccination schedule for a candidate toxoid vaccine to
able 3
olicited injection site and systemic adverse reactions occurring in the 7 days after any d
Stage I 
Adverse reaction Group 1
(N = 100)
Group 2
(N = 102a)
Group 3
(N = 101)
Any solicited reaction 70.1 (60.0;79.0) 69.7 (59.6;78.5) 75.2 (65.7;83.3) 
Injection site reactions: 53.6 (43.2;63.8) 43.4 (33.5;53.8) 54.5 (44.2;64.4) 
Pain  52.6 (42.2;62.8) 42.4 (32.6;52.8) 52.5 (42.3;62.5) 
Erythema 5.2 (1.7;11.6) 3.0 (0.6;8.6) 6.9 (2.8;13.8) 
Swelling 6.2 (2.3;13.0) 1.0 (0.0;5.5) 5.0 (1.6;11.2) 
Systemic reactions: 58.8 (48.3;68.7) 57.6 (47.2;67.5) 58.4 (48.2;68.1) 
Fever  5.3 (1.7;11.9) 6.1 (2.3;12.7) 1.0 (0.0;5.4) 
Headache 35.4 (25.9;45.8) 27.3 (18.8;37.1) 31.7 (22.8;41.7) 
Malaise 32.0 (22.9;52.2) 32.3 (23.3;42.5) 33.7 (24.6;43.8) 
Myalgia 37.1 (27.5;47.5) 33.3 (24.2;43.5) 42.6 (32.8;52.8) 
Arthralgia 27.8 (19.2;37.9) 20.2 (12.8;29.5) 23.8 (15.9;33.3) 
ata are number of participants experiencing at least one reaction (95% CI).
 = number of participants included in the safety analysis set (not necessarily the number
a One subject, even though randomized to Group 1, received Group 2 treatment at all 3conﬁdence intervals (Day 0–180) (Groups 3, 6, 7) (PP set).
protect against CDI to be used in Phase 3 clinical development. The
dose levels in Stage I (50 and 100 g) were chosen based on Phase I
studies in healthy adult and elderly volunteers [20], in which doses
up to 50 g had been used. The response using the 50 g dose level
had been strong for toxin A but was lower than expected for toxin
B, and so this dose was  used as a starting dose in the present study,
with the 100 g dose level being included to evaluate whether the
increased dose would result in an improved response for toxin B
and also to assess whether the higher dose would be associated
with a more rapid response. The vaccination schedules chosen for
assessment in Stage II were comparatively evaluated based on the
goal of achieving an immune response by Day 14 and with prioritythis represents typical waiting times for planned, non-emergent,
major surgical procedures [22]. The majority of participants were
enrolled prior to a planned hospitalization, and most were admitted
ose of vaccine (safety analysis set).
Stage II
Group 4
(N = 102)
Group 5
(N = 50)
Group 6
(N = 103)
Group 7
(N = 102)
69.8 (59.6;78.7) 43.8 (29.5;58.8) 82.2 (73.3;89.1) 83.0 (74.2;89.8)
58.3 (47.8;68.3) 25.0 (13.6;39.6) 70.3 (60.4;79.0) 66.0 (55.8;75.2)
57.3 (46.8;67.3) 25.0 (13.6;39.6) 68.3 (58.3;77.2) 65.0 (54.8;74.3)
10.4 (5.1;18.3) 0.0 (0.0;7.4) 11.9 (6.3;19.8) 5.0 (1.6;11.3)
4.2 (1.1;10.3) 0.0 (0.0;7.4) 9.9 (4.9;17.5) 8.0 (3.5;15.2)
52.1 (41.6;62.4) 37.5 (24.0;52.6) 64.4 (54.2;73.6) 62.0 (51.7;71.5)
0.0 (0.0;3.8) 0.0 (0.0;7.4) 5.9 (2.2;12.5) 3.0 (0.6;8.5)
30.2 (21.3;40.4) 18.8 (8.9;32.6) 35.6 (26.4;45.8) 32.0 (23.0;42.1)
31.3 (22.2;41.5) 20.8 (10.5;35.0) 30.7 (21.9;40.7) 29.0 (20.4;38.9)
34.4 (25.0;44.8) 20.8 (10.5;35.0) 38.6 (29.1;48.8) 45.0 (35.0;55.3)
24.0 (15.8;33.7) 12.5 (4.7;25.2) 26.7 (18.4;36.5) 30.0 (21.2;40.0)
 of participants available for a particular endpoint).
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o hospital within a short interval after enrolment. The effect of the
lOH adjuvant was evaluated as it was considered likely that an
djuvant would be necessary to optimize the immune response,
articularly in elderly patients or those with co-morbidities
ho comprise a large proportion of the population at risk
f CDI.
All vaccine formulations and schedules demonstrated a clini-
ally acceptable safety proﬁle, and a comparison of the immune
esponses based on the formulation (in Stage I) and schedule (in
tage II) resulted in the 100 g + AlOH formulation and the 0, 7, 30
ay schedule being selected for further clinical development of the
andidate vaccine. The higher dose and inclusion of the adjuvant
mproved the response to toxin B, which had been suboptimal in
arlier studies [20] and, when given at 0, 7, and 30 days, resulted
n good response kinetics in terms of the response at Day 14 and
ay 60.
Health-care acquired CDI is most likely to occur between 3
nd 5 days after exposure to C. difﬁcile spores [23]. Additionally,
t has been shown that 85% of nosocomial CDI cases occur within 1
onth of discharge from hospital, and the remainder occur within
 months of discharge [23]. The average waiting time for planned
urgery has been estimated at between 2 weeks to 5 months, and so
he immune response proﬁle at Day 60 that was sustained through
ay 180 was prioritized in the selection of the optimal formulation
nd schedule. Using these criteria, the formulation and the 0, 7, 30
ay schedule selected would optimize protection not only during
ospitalization but also after discharge.
The vaccine is being developed to protect patients with chronic
nderlying medical conditions who are likely to have hospital stays
nd/or receive antibacterials in the future, and to be given on an
ut-patient basis prior to hospitalization (e.g. for elective surgery).
s such, individuals would ideally be immunized in advance of
xposure to C. difﬁcile spores using the 0, 7, 30 day schedule, which
ould begin to provide a protective immune response as early as
ay 14 and which may  be augmented and sustained after a third
ose on Day 30. In this way, protection could be provided to at-
isk patients before entering the period of highest risk. Provision of
nother dose on (Stage I of this study) or after Day 30 (Stage II of this
tudy) results in further augmentation of immune responses, indi-
ating the potential for sustaining immune responses. Additionally,
t is likely that vaccination compliance in a real life setting would be
etter for a shorter schedule, again favoring the 0, 7, 30 day sched-
le (Groups 1–5) over one that continues to Day 180 (Groups 6 and
); this was conﬁrmed in the present study with overall completion
ates of 91.4% in Groups 1–5 and 81.6% in Groups 6 and 7.
As there is no known immunological correlate of protection
gainst CDI, it is unclear whether the investigational immunologic
easures assessed may  be predictive of vaccine efﬁcacy. How-
ver, the vaccine formulations tested induced both neutralizing and
inding antibodies, both of which are considered to be valid options
or the choice of formulation and schedule, and the responses for
oth ELISA and TNA persisted over the course of the study. Contin-
ed persistence will be evaluated and deﬁned through extended
ollow-up.
Based on the results of this Phase 2 study, the adjuvanted high-
ose candidate vaccine formulation administered with a 0, 7, 30
ay schedule was selected for further clinical evaluation. Vaccine
fﬁcacy, including duration of response against the primary (ﬁrst
ccurrence) symptomatic CDI episode is currently being assessed
n an ongoing, multinational Phase 3 efﬁcacy study.cknowledgements
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